ADI-001 for Autoimmune Diseases - Adicet's ADI-001 targets CD20 and has demonstrated complete CD19+ B cell depletion in blood and secondary lymphoid tissue[8, 17] - ADI-001 is under clinical development for 6 autoimmune indications, with initial clinical data expected in the second half of 2025[8, 9] - ADI-001's Cmax, D28 Persistence, and AUC are consistent with approved autologous CD19 CAR T therapies[19] - In preclinical studies, ADI-001 exhibited potent killing of patient-derived CD19+ B cells in multiple autoimmune diseases, including SLE, SSc, RA, Multiple Sclerosis, and Sjogren's Syndrome[25] - A Phase 1 autoimmune study is underway, with primary endpoints focused on safety and secondary endpoints including cellular kinetics, pharmacodynamics, and efficacy endpoints specific to each indication[57, 59] - The company is expanding ADI-001 autoimmune development across six indications with a US prevalence of ~242 thousand patients for SLE, ~85 thousand for Systemic Sclerosis, ~60 thousand for IIM, ~60 thousand for AAV and so on[50, 51] ADI-270 for Oncology - Adicet's ADI-270 targets CD70 and is designed to address multiple refractory cancers, with a Phase 1 clinical update expected in the second half of 2025[8, 62, 64] - ADI-270 incorporates a TGFβ receptor II to mitigate immunosuppressive effects and is engineered to increase persistence[8, 65] - Preclinical data shows ADI-270 retains potent activity in CD70-low tumors compared to clinically relevant CD70-targeting αβ CAR T cell benchmarks[79] - In ccRCC xenograft models, a single dose of ADI-270 demonstrated potent regression and sustained systemic anti-tumor activity[92] Financial Status - As of March 31, 2025, Adicet Bio has approximately $1504 million in cash and cash equivalents, projected to provide a cash runway into the second half of 2026[101]